Starting at age 40, you lose 1 to 2% of your muscle mass each year. It sounds insignificant—until you realize that by the time you’re 70, this could mean losing as much as 30–40% of the total muscle mass you had at your peak. Sarcopenia—as this condition is called—is not just a matter of aesthetics or strength. It is one of the main predictors of disability, falls, metabolic diseases, and premature death. And yet, most people have never heard of it—and only start taking action once the problem has become serious. This article changes that.
What is sarcopenia and why does it affect all of us?
The term “sarcopenia” comes from the Greek: sarx (body, flesh) and penia (loss, deficiency). The concept was introduced into scientific literature by Irwin Rosenberg in 1989 to describe the progressive loss of skeletal muscle mass and function that occurs with age. For years, it was regarded as a natural, inevitable consequence of aging. Today we know that this is a misconception—sarcopenia is a modifiable condition, and its progression can be effectively managed.
In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) developed the first standardized diagnostic criteria, which were updated in 2019 (EWGSOP2). According to these criteria, sarcopenia is defined as a progressive and generalized disorder of skeletal muscle, associated with an increased risk of adverse health outcomes, including falls, fractures, physical disability, and mortality (Cruz-Jentoft et al., Age and Ageing, 2019).
The scale of the problem is enormous. It is estimated that sarcopenia affects 10–27% of people over the age of 60, and in the population over 80 – every other person. According to the SHARE (Survey of Health, Ageing and Retirement in Europe) study conducted in 27 European countries, sarcopenia rates among Europeans over the age of 65 range between 12 and 33%, depending on the population and diagnostic criteria applied (Beaudart et al., Osteoporosis International, 2014).
Why do we lose muscle after 40? Biological mechanisms
Sarcopenia does not have a single cause – it is the result of several overlapping biological processes that mutually reinforce one another.
1. Denervation and loss of motor units
Every muscle is controlled by motor neurons that form so-called motor units with muscle fibres. After the age of 60, the number of alpha motor neurons in the spinal cord decreases by 25–50%, leading to the "orphaning" of muscle fibres – they lose innervation and gradually atrophy. The study by Lexell et al. (Journal of the Neurological Sciences, 1988) showed that the number of muscle fibres in the quadriceps femoris decreases between the ages of 20 and 80 by approximately 39%, and these changes begin to be visible after the age of 40.
2. Mitochondrial dysfunction and oxidative stress
Mitochondria in muscle cells are particularly susceptible to oxidative damage. With age, so-called "mitochondrial dysfunction" increases – mitochondrial density decreases, the activity of the respiratory chain and ATP production decline. At the same time, production of reactive oxygen species (ROS) increases, damaging muscle proteins and DNA. The study by Safdar et al. (PNAS, 2011) showed that the accumulation of mitochondrial DNA mutations in muscle cells is a key driving mechanism of sarcopenia – and that it can be partially reversed through endurance exercise.
3. Impaired muscle protein synthesis (anabolic resistance)
A healthy muscle constantly balances between the synthesis and breakdown of muscle proteins. After the age of 40, so-called "anabolic resistance" appears – the resistance of muscles to anabolic stimuli, including amino acids (particularly leucine) and insulin. This means that the same protein meal that effectively stimulates muscle protein synthesis in a 25-year-old may not produce a sufficient response in a person over 50. The study by Cuthbertson et al. (FASEB Journal, 2005) was the first to describe and quantitatively measure this phenomenon, showing that the leucine threshold triggering protein synthesis increases with age.
4. Chronic inflammation (inflammaging)
The concept of "inflammaging" – the chronic, low-grade inflammation accompanying aging – was introduced by Claudio Franceschi in 2000. Pro-inflammatory cytokines, particularly IL-6 and TNF-α, activate the ubiquitin-proteasome pathway, which accelerates the breakdown of muscle proteins. At the same time, they inhibit the mTORC1 pathway responsible for the synthesis of new proteins. The study by Visser et al. (Journal of the American Geriatrics Society, 2002) showed that high levels of IL-6 and CRP in people over the age of 70 were independent predictors of loss of muscle mass and strength over 3 years of observation.
5. Hormonal changes
Testosterone, estrogens, growth hormone (GH), and insulin-like growth factor 1 (IGF-1) are the primary anabolic hormones that support muscle protein synthesis. All of these decline steadily with age: testosterone in men decreases by 0.5–2% per year after age 30, while GH and IGF-1 decrease by 14–15% per decade. In women, menopause causes a sharp decline in estrogen, which—contrary to popular belief—plays a significant role in maintaining muscle mass and strength. A study by Baumgartner et al. (American Journal of Epidemiology, 1999) showed that low testosterone levels in men and low estrogen levels in women were independent risk factors for sarcopenia.
6. Protein malnutrition and micronutrient deficiencies
Many people over 40 unknowingly consume too little protein. Yet, as anabolic resistance increases, the body needs more protein, not less. Deficiencies in vitamin D, magnesium, and omega-3 fatty acids directly impair muscle function—a topic we’ll discuss in more detail in the section on supplementation.
How to recognise sarcopenia? Warning signs and diagnostics
Sarcopenia remains asymptomatic for many years, or its symptoms are mistakenly interpreted as "natural aging". It is worth paying attention to the following signals:
- difficulty getting up from a chair or from the floor without using your hands,
- slower walking pace than in the past,
- weakened hand grip,
- increasing fatigue during daily activities,
- unexplained weight loss (especially when fat mass is preserved or increasing – so-called "sarcopenic obesity"),
- more frequent falls or a feeling of imbalance.
Screening tests available without specialist equipment
- SARC-F questionnaire – a 5-item questionnaire regarding strength, assistance with walking, standing up from a chair, climbing stairs, and frequency of falls. A score of ≥4 points suggests sarcopenia (Malmstrom et al., Journal of the American Medical Directors Association, 2013).
- Grip Strength Test – a handheld dynamometer costs 30–80 PLN. Values below 27 kg for men and 16 kg for women are considered by EWGSOP2 to be diagnostic criteria for sarcopenia.
- 5-Times Chair Stand Test – measure the time required to stand up and sit down 5 times without using the hands. A time exceeding 15 seconds suggests reduced leg muscle function.
- Calf circumference measurement – a calf circumference below 31 cm is a simple, validated indicator of reduced muscle mass in older adults (Rolland et al., Journal of the American Geriatrics Society, 2003). NOTE: In cases of obesity, this measurement should not be used as an indicator of sarcopenia. Adipose tissue may mask the actual condition of skeletal muscle.
Full diagnosis of sarcopenia requires body composition measurement (DXA, BIA) and muscle function assessment, but the above tests allow for effective screening even at home.
Consequences of sarcopenia – why it pays to act early
Sarcopenia is much more than a loss of strength. Its systemic consequences are far-reaching and interconnected.
Skeletal muscles constitute the main reservoir of amino acids and the largest "sink" for glucose in the body (accounting for 70–80% of insulin-dependent glucose uptake). Loss of muscle mass directly reduces insulin sensitivity and increases the risk of type 2 diabetes and metabolic syndrome. The study by Srikanthan et al. (Journal of Clinical Endocrinology & Metabolism, 2011) showed that a higher muscle index was independently associated with lower insulin resistance – regardless of fat mass.
Muscles also perform an endocrine function: they secrete myokines (including irisin, IL-6 during exercise, and BDNF), which protect the brain, bones, and cardiovascular system. Research by Boström et al. (Nature, 2012) showed that irisin—secreted by active muscles—stimulates neurogenesis in the hippocampus. Preclinical studies have demonstrated that irisin may delay neurodegenerative processes. In other words: by losing muscle, we also lose protection for the brain.
A meta-analysis by Beaudart et al. (Journal of Nutrition, Health & Aging, 2017), encompassing 35 studies, confirmed that sarcopenia is an independent risk factor for all-cause mortality, hospitalization, falls, and fractures. Individuals with sarcopenia had more than twice the risk of death over a 5-year follow-up period compared to those with normal muscle mass and function.
How to prevent and reverse sarcopenia? Three pillars of intervention
Pillar 1: Resistance training – the most powerful tool
No diet or supplement can replace resistance training in the context of sarcopenia. Exercises with load stimulate the mTORC1 pathway, activate satellite cells (muscle stem cells) and increase mitochondrial density – and all these processes are impaired by aging.
The meta-analysis by Peterson et al. published in the American Journal of Medicine (2011), covering 47 randomised trials with over 1,000 participants aged 50–90, showed that progressive resistance training increased muscle strength by an average of 26.6% and muscle mass by 1.1 kg over 20 weeks – even in people over the age of 80. This is a landmark result: it means that muscles retain their capacity for adaptation regardless of age.
Recommended protocol according to the American College of Sports Medicine (ACSM) guidelines: 2–3 sessions per week, 2–4 sets of 8–12 repetitions per muscle group, with progressive increase in load. Key muscle groups for functionality and fall prevention: leg muscles (quadriceps, hamstrings, calves), gluteal muscles, core and back muscles.
Pillar 2: Protein – how much, when and what type?
Current guidelines for physically active people over the age of 50 recommend a protein intake of 1.2–1.6 g per kilogram of body weight per day – significantly more than the standard 0.8 g/kg/day recommended for the general adult population. In states of sarcopenia or during intensive training, the requirement may rise to 1.6–2.2 g/kg/day.
Just as important as quantity is the distribution of protein throughout the day. The study by Areta et al. (Journal of Physiology, 2013) showed that spreading protein intake across 3–4 meals (with 20–40 g of high-quality protein in each) stimulates muscle protein synthesis more effectively than consuming the same amount in one or two large meals.
Leucine is particularly important – a branched-chain amino acid (BCAA) that acts as an "anabolic switch", directly activating the mTORC1 pathway. The leucine threshold triggering optimal protein synthesis increases with age: while in young adults it is ~2 g of leucine per meal, in people over 65 it may be ~3 g. In practical terms, this means it is worth choosing proteins with a high leucine content: whey protein (~10–11% leucine), meat, fish, eggs.
Pillar 3: Supplementation – what really works?
Supplementation cannot replace diet and training, but it can significantly enhance their effects – particularly in the face of increasing anabolic resistance and greater demand for mitochondrial cofactors.
Creatine
Creatine is the most extensively studied supplement in the context of sarcopenia and muscle function in older adults. A meta-analysis by Devries and Phillips (Medicine & Science in Sports & Exercise, 2014), encompassing 22 randomized trials, showed that creatine supplementation combined with resistance training increased muscle strength and lean body mass to a significantly greater extent than training alone. Importantly, the benefits were more pronounced in older adults than in younger ones—because older muscles have lower phosphocreatine levels and benefit more from supplementation.
Recommended dose: 3–5 g of creatine monohydrate daily. The creatine gummy form—available from LLMe—allows for convenient, regular dosing without the need to mix powders—which is crucial for adherence, especially among non-professional athletes.
Vitamin D3 + K2
Vitamin D receptors (VDR) are present in muscle cells, where they regulate muscle protein synthesis and the transport of calcium necessary for muscle contraction. The meta-analysis by Beaudart et al. (Journal of Clinical Endocrinology & Metabolism, 2014), covering 30 studies, showed that vitamin D supplementation in people with its deficiency improved muscle strength and reduced the risk of falls. The target level of 25(OH)D3 in serum is 40–80 ng/mL. Vitamin K2 (MK-7) is essential for proper calcium metabolism – it directs calcium to bones and muscles, preventing its deposition in blood vessels.
Omega-3 (EPA and DHA)
Omega-3 fatty acids exert a direct anti-sarcopenic effect in two ways. First, they have anti-inflammatory effects, reducing levels of IL-6 and TNF-α, which drive muscle catabolism. Second, they stimulate the mTORC1 pathway and muscle protein synthesis independently of exercise. A study by Smith et al. (American Journal of Clinical Nutrition, 2011) showed that supplementation with 4 g of EPA+DHA daily for 8 weeks increased the rate of muscle protein synthesis in healthy middle-aged and older adults by 26%—a result comparable to moderate resistance training.
Magnesium
Magnesium is a cofactor of ATPase and over 300 metabolic enzymes. Its deficiency directly impairs muscle contractility, recovery after exercise and protein synthesis. The study by Dominguez et al. (American Journal of Clinical Nutrition, 2006) showed that higher magnesium intake was independently associated with greater muscle strength and better muscle function in women over the age of 60. Worryingly, it is estimated that the majority of European adults do not reach the recommended daily intake of magnesium.
Coenzyme Q10
CoQ10 is an essential component of the mitochondrial respiratory chain. Its deficiency – naturally increasing after the age of 30 and accelerated by statins (one of the most commonly prescribed medications after 50) – directly reduces ATP production in muscle cells. The study by Cooke et al. (Journal of the International Society of Sports Nutrition, 2008) showed that CoQ10 supplementation reduced training-induced muscle damage and accelerated recovery.
NR (Nicotinamide Riboside)
NAD+ levels in muscle tissue decline by 50–60% between the ages of 40 and 70, which directly impairs the activity of sirtuins (SIRT1, SIRT3) that regulate mitochondrial biogenesis and autophagy in muscles. The study by Zhang et al. (Cell Metabolism, 2016) showed that supplementation with an NAD+ precursor (NMN) in mice with sarcopenia restored mitochondrial function in muscles and improved physical performance. Clinical studies with NR in humans (Martens et al., Nature Communications, 2018) confirmed effective elevation of NAD+ levels in tissues.
Sarcopenic obesity – a double threat
Particularly dangerous is so-called sarcopenic obesity – a state in which loss of muscle mass and gain in fat tissue, particularly visceral fat, occur simultaneously. A person with sarcopenic obesity may have a normal or even high BMI, which makes the problem difficult to detect without body composition measurement.
Visceral fat tissue secretes pro-inflammatory adipokines (leptin, resistin, TNF-α), which directly intensify muscle catabolism – creating a vicious cycle: the more fat, the faster the muscle loss, and the less muscle, the lower the calorie burn and the easier the fat gain. The study by Baumgartner et al. (Obesity Research, 2004) showed that people with sarcopenic obesity had significantly higher risk of functional disability than people with sarcopenia alone or obesity alone.
A practical action plan – what to do this week
Step 1: Assess your baseline
Perform the grip strength test (dynamometer or roughly: can you unscrew a jar of jam without difficulty?), the chair stand test (5 times without using your hands – how long does it take?) and measure your calf circumference. Record the results – they will be your reference point.
Step 2: Introduce resistance training 2–3 times a week
You don't need to join a gym – squats, press-ups, lunges and exercises with resistance bands at home are entirely sufficient to start. The key is progression: each week, do a little more – one more repetition, slightly more resistance.
Step 3: Verify your protein intake
For 3 days, write down everything you eat and calculate your protein intake (apps like Cronometer or MyFitnessPal make this easier). If you’re consuming less than 1.2 g per kilogram of body weight, start consciously increasing your intake: add an egg to breakfast, a serving of fish or meat to lunch, and Greek yogurt to dinner.
Step 4: Address key deficiencies
Get your vitamin D (25(OH)D3) levels and complete blood count checked—this is essential. Consider supplementation with creatine (3–5 g/day), vitamin D3+K2 (dose depending on test results), magnesium (300–400 mg/day in the evening in the form of magnesium citrate or glycinate), and Omega-3 (2–4 g EPA+DHA/day).
Step 5: Monitor progress every 4–6 weeks
Repeat the tests from Step 1 and observe the trends. Real, measurable improvement in grip strength or chair stand test time after 8–12 weeks of intervention is the best evidence that your protocol is working.
Summary: muscles are a longevity organ
For decades, muscles were treated solely as "engines of movement". Today, science views them as an active endocrine, metabolic and immunological organ – crucial for brain health, glucose regulation, bone protection and overall resistance to aging. Muscle loss is not a "natural effect of aging that nothing can be done about" – it is a modifiable process that can be effectively slowed or reversed at any stage of life.
The research is unequivocal: it is never too late to start. People over the age of 80 who took up resistance training recorded significant improvements in muscle strength and mass. And those who begin acting after the age of 40 – before the first symptoms appear – have the opportunity to enter subsequent decades with a body that is strong, fit and resilient. That is what true longevity really means.
References and sources
- Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., ... & Zamboni, M. (2019). Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31. https://doi.org/10.1093/ageing/afy169
- Beaudart, C., Rizzoli, R., Bruyère, O., Reginster, J. Y., & Biver, E. (2014). Sarcopenia: burden and challenges for public health. Archives of Public Health, 72(1), 45. https://doi.org/10.1186/2049-3258-72-45
- Lexell, J., Taylor, C. C., & Sjöström, M. (1988). What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. Journal of the Neurological Sciences, 84(2–3), 275–294. https://doi.org/10.1016/0022-510X(88)90132-3
- Safdar, A., Bourgeois, J. M., Ogborn, D. I., Little, J. P., Hettinga, B. P., Akhtar, M., ... & Tarnopolsky, M. A. (2011). Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. PNAS, 108(10), 4135–4140. https://doi.org/10.1073/pnas.1019581108
- Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., ... & Rennie, M. J. (2005). Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB Journal, 19(3), 422–424. https://doi.org/10.1096/fj.04-2640fje
- Visser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., ... & Harris, T. B. (2002). Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women. Journal of the American Geriatrics Society, 50(5), 827–834. https://doi.org/10.1046/j.1532-5415.2002.50207.x
- Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999). Predictors of skeletal muscle mass in elderly men and women. Maturitas, 31(3), 245–251. https://doi.org/10.1016/S0378-5122(99)00006-8
- Peterson, M. D., Rhea, M. R., Sen, A., & Gordon, P. M. (2010). Resistance exercise for muscular strength in older adults: a meta-analysis. Ageing Research Reviews, 9(3), 226–237. https://doi.org/10.1016/j.arr.2010.03.004
- Areta, J. L., Burke, L. M., Ross, M. L., Camera, D. M., West, D. W., Broad, E. M., ... & Coffey, V. G. (2013). Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. Journal of Physiology, 591(9), 2319–2331. https://doi.org/10.1113/jphysiol.2012.244897
- Devries, M. C., & Phillips, S. M. (2014). Creatine supplementation during resistance training in older adults—a meta-analysis. Medicine & Science in Sports & Exercise, 46(6), 1194–1203. https://doi.org/10.1249/MSS.0000000000000220
- Beaudart, C., Buckinx, F., Rabenda, V., Gillain, S., Cavalier, E., Slomian, J., ... & Reginster, J. Y. (2014). The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Endocrinology & Metabolism, 99(11), 4336–4345. https://doi.org/10.1210/jc.2014-1742
- Smith, G. I., Atherton, P., Reeds, D. N., Mohammed, B. S., Rankin, D., Rennie, M. J., & Mittendorfer, B. (2011). Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia–hyperaminoacidaemia in healthy young and middle-aged men and women. Clinical Science, 121(6), 267–278. https://doi.org/10.1042/CS20100597
- Dominguez, L. J., Barbagallo, M., Lauretani, F., Bandinelli, S., Bos, A., Corsi, A. M., ... & Ferrucci, L. (2006). Magnesium and muscle performance in older persons: the InCHIANTI study. American Journal of Clinical Nutrition, 84(2), 419–426. https://doi.org/10.1093/ajcn/84.1.419
- Srikanthan, P., & Karlamangla, A. S. (2011). Relative muscle mass is inversely associated with insulin resistance and prediabetes. Journal of Clinical Endocrinology & Metabolism, 96(9), 2898–2903. https://doi.org/10.1210/jc.2011-0435
- Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., ... & Spiegelman, B. M. (2012). A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463–468. https://doi.org/10.1038/nature10777
- Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., ... & Auwerx, J. (2016). NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science, 352(6292), 1436–1443. https://doi.org/10.1126/science.aaf2693
- Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J. Y., & Bruyère, O. (2017). Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS ONE, 12(1), e0169548. https://doi.org/10.1371/journal.pone.0169548
- Baumgartner, R. N., Wayne, S. J., Waters, D. L., Janssen, I., Gallagher, D., & Morley, J. E. (2004). Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obesity Research, 12(12), 1995–2004. https://doi.org/10.1038/oby.2004.250
About the author:
